Prevalence of comorbid factors in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a randomized trial of an oral microbiota-based therapeutic.
Charles S BerensonBret LashnerLouis KormanElizabeth HohmannAbhishek DeshpandeThomas J LouieMatthew SimsDarrell PardiColleen KraftElaine E L WangStuart H CohenPaul FeuerstadtCaterina OnetoBharat MisraJohn PullmanAnanya DeAsli MemisogluDavid A LombardiBrooke R HassonBarbara H McGovernLisa von MoltkeChristine LeePublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
In this post-hoc analysis, VOS reduced the risk of rCDI compared with placebo, regardless of baseline characteristics, concomitant medications or comorbidities.